In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million ...
According to a report from CNN, more states and pediatricians are now choosing the AAP’s guidance over a revised federal ...
Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...
Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results